Medicare details structure of new drug price negotiation; Duchenne breakthrough therapy leaves behind pioneering families

Taking stock of the drug industry, from the lab to the medicine chest

June 30, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

APStock STAT+ | Medicare details the structure of its new drug price negotiation program Medicare on Friday released new details about how its new drug price negotiation program will work, just two months before it's set to start. By Rachel Cohrs and Sarah Owermohle and John Wilkerson STAT+ | Medicare's new proposal to cover medical devices draws a mixed reaction Medical device makers have long complained that the rocky road to Medicare reimbursement kills innovative companies. By Lizzy Lawrence STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman Dr. Edwin P. Ewing, Jr./CDC For Duchenne moms who pushed for cures, new breakthrough therapy can't rebuild what's lost Their sons paved the way for approval of Sarepta Therapeutics' gene therapy, Elevidys — but only for younger patients. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser